Overview

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

Status:
Terminated

Trial end date:
2017-03-27

Target enrollment:

Participant gender:

Summary

To demonstrate that Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) delivered subcutaneously via auto-injector is associated with less pain as compared to intramuscular injections of Makena®

Phase:

Phase 3

Details

Lead Sponsor:

AMAG Pharmaceuticals, Inc.

Treatments:

11-hydroxyprogesterone
17 alpha-Hydroxyprogesterone Caproate
17-alpha-hydroxy-progesterone caproate